Health
Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?
By Marcus Chen
A failed trial for a heart drug casts shadow over rivals developing similar therapies
Katherine Langford
Katherine Langford
Editor-in-Chief · Edina, MN
Katherine oversees editorial operations across all six brands. Before joining The Meridan Group, she spent 14 years at the Minneapolis Star Tribune, where she led the metro desk through its digital transformation. She holds a Master's in Journalism from Northwestern's Medill School.
More from Katherine →Editor-in-Chief · Monday, November 9, 2026 at 1:54 PM · 1 min read
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Up nextCould supplements be the next big opportunity in the GLP-1 weight-loss drug boom?Health · 4 min read
More Health stories
Health
Richard Simmons’ L.A. estate sells for $3.8 million
By Katherine Langford
Health
CVS Health plans to split in two. Here’s what is driving the massive healthcare breakup.
By Katherine Langford
Health
When you turn this age, it’s your best chance to get crucial tax and healthcare plans in place for retirement
By Marcus Chen